{"altmetric_id":4685956,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Bavarian Nordic"],"first_seen_on":"2015-10-28T11:56:29+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1439913843,"links":["https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02419391"],"nct_id":"NCT02419391","pubdate":"2015-04-07T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN\u00ae RSV Vaccine","type":"clinical_trial_study_record"},"altmetric_score":{"score":19,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":19},"context_for_score":{"all":{"total_number_of_other_articles":5557533,"mean":6.3234115848551,"rank":285279,"this_scored_higher_than_pct":94,"this_scored_higher_than":5270247,"rank_type":"exact","sample_size":5557533,"percentile":94},"similar_age_3m":{"total_number_of_other_articles":201405,"mean":10.212766519036,"rank":17883,"this_scored_higher_than_pct":91,"this_scored_higher_than":183461,"rank_type":"exact","sample_size":201405,"percentile":91},"this_journal":{"total_number_of_other_articles":14829,"mean":7.6408371998921,"rank":725,"this_scored_higher_than_pct":95,"this_scored_higher_than":14094,"rank_type":"exact","sample_size":14829,"percentile":95},"similar_age_this_journal_3m":{"total_number_of_other_articles":784,"mean":12.219918263091,"rank":55,"this_scored_higher_than_pct":92,"this_scored_higher_than":728,"rank_type":"exact","sample_size":784,"percentile":92}}},"demographics":[],"counts":{"total":{"posts_count":4},"news":{"unique_users_count":4,"unique_users":["town_hall","biospace","good_day_sacramento","bioportfolio"],"posts_count":4}},"posts":{"news":[{"title":"Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN(r) in Respiratory Syncitial Virus (RSV)","url":"http:\/\/ct.moreover.com\/?a=22347348588&p=1pl&v=1&x=WV77UlgR5aiTHiusEWbjgw","license":"public","citation_ids":[4685956],"posted_on":"2015-08-18T14:09:20+00:00","summary":"COPENHAGEN, Denmark, Aug. 18, 2015 (GLOBE NEWSWIRE) -- Bavarian Nordic A\/S (OMX: BAVA, OTC: BVNRY ) today announced the initiation of a Phase 1 clinical study of its MVA-BN \u00ae RSV vaccine candidate against respiratory syncytial virus (RSV), the first\u2026","author":{"name":"Town Hall","url":"http:\/\/www.townhall.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/373\/normal\/Screenshot_2015-07-17_14.35.23.png?1437140149"}},{"title":"Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN\u00ae in Respiratory Syncitial Virus (RSV)","url":"http:\/\/ct.moreover.com\/?a=22347358806&p=1pl&v=1&x=Ufv8g2TZqV2TnILB2Yc98Q","license":"public","citation_ids":[4685956],"posted_on":"2015-08-18T14:04:09+00:00","summary":"COPENHAGEN, Denmark - August 18, 2015 - Bavarian Nordic A\/S (OMX: BAVA, OTC: BVNRY ) today announced the initiation of a Phase 1 clinical study of its MVA-BN \u00ae RSV vaccine candidate against respiratory syncytial virus (RSV), the first study to\u2026","author":{"name":"Biospace","url":"http:\/\/www.biospace.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/375\/normal\/biospace.png?1437140433"}},{"title":"Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN(r) in Respiratory Syncitial Virus (RSV)","url":"http:\/\/ct.moreover.com\/?a=22347388702&p=1pl&v=1&x=G-FYc3B9LC_SqPp4yjdtXQ","license":"public","citation_ids":[4685956],"posted_on":"2015-08-18T14:09:20+00:00","summary":"COPENHAGEN, Denmark, Aug. 18, 2015 (GLOBE NEWSWIRE) -- Bavarian Nordic A\/S (OMX: BAVA, OTC: BVNRY ) today announced the initiation of a Phase 1 clinical study of its MVA-BN \u00ae RSV vaccine candidate against respiratory syncytial virus (RSV), the first\u2026","author":{"name":"Good Day Sacramento","url":"http:\/\/gooddaysacramento.cbslocal.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/376\/normal\/Screenshot_2015-07-17_14.38.00.png?1437140481"}},{"title":"Bavarian Nordic Initiates Phase 1 Clinical Trial of MVABN\u00c2 in Respiratory Syncitial Virus RSV","url":"http:\/\/www.bioportfolio.com\/news\/article\/2432664\/Bavarian-Nordic-Initiates-Phase-1-Clinical-Trial-of-MVA-BN-in-Respiratory.html","license":"public","citation_ids":[4685956],"posted_on":"2015-08-18T16:04:03+00:00","summary":"COPENHAGEN Denmark August 18 2015 Bavarian Nordic AS OMX BAVA OTC BVNRY today announced the initiation of a Phase 1 clinical study of its MVABN\u00c2 RSV vaccine candidate against respiratory syncytial virus RSV the first study to evaluate the vaccine candi...","author":{"name":"Bioportfolio","url":"http:\/\/www.bioportfolio.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/821\/normal\/Screen_Shot_2015-12-11_at_16.36.54.png?1449851849"}}]}}